Symbiotec Pharmalab Ltd
- Market Cap ₹ 7,033 Cr.
- Current Price ₹ 1,093
- High / Low ₹ 1,180 / 934
- Stock P/E 61.0
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 13.0 %
- ROE 11.7 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
Cons
- Promoter holding is low: 33.3%
- Company has a low return on equity of 12.9% over last 3 years.
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| 633 | 682 | 567 | 716 | 752 | 869 | |
| 438 | 550 | 497 | 544 | 549 | 630 | |
| Operating Profit | 195 | 131 | 70 | 172 | 203 | 239 |
| OPM % | 31% | 19% | 12% | 24% | 27% | 27% |
| 7 | 3 | 6 | 7 | 4 | -6 | |
| Interest | 7 | 3 | 8 | 8 | 17 | 26 |
| Depreciation | 22 | 26 | 29 | 39 | 43 | 53 |
| Profit before tax | 173 | 105 | 39 | 132 | 147 | 153 |
| Tax % | 28% | 27% | 38% | 23% | 34% | 28% |
| 123 | 78 | 23 | 100 | 97 | 110 | |
| EPS in Rs | 112.72 | 70.89 | 21.48 | 91.49 | 151.98 | 17.51 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 7% |
| 3 Years: | 15% |
| TTM: | 16% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -1% |
| 3 Years: | 70% |
| TTM: | 19% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 12% |
| 3 Years: | 13% |
| Last Year: | 12% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 11 | 11 | 11 | 11 | 11 | 13 |
| Reserves | 510 | 588 | 611 | 704 | 804 | 1,137 |
| 47 | 65 | 218 | 247 | 544 | 391 | |
| 200 | 152 | 151 | 326 | 220 | 240 | |
| Total Liabilities | 768 | 815 | 990 | 1,289 | 1,580 | 1,781 |
| 261 | 280 | 299 | 448 | 438 | 1,120 | |
| CWIP | 28 | 40 | 182 | 208 | 568 | 64 |
| Investments | 5 | 5 | 5 | 4 | 1 | 4 |
| 474 | 490 | 504 | 628 | 572 | 592 | |
| Total Assets | 768 | 815 | 990 | 1,289 | 1,580 | 1,781 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| 174 | 18 | 69 | 188 | 47 | 175 | |
| -96 | -32 | -220 | -206 | -307 | -227 | |
| -79 | 15 | 146 | 22 | 278 | 36 | |
| Net Cash Flow | -1 | 1 | -5 | 3 | 19 | -16 |
| Free Cash Flow | 87 | -55 | -155 | -22 | -261 | -50 |
| CFO/OP | 112% | 36% | 124% | 129% | 40% | 99% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 68 | 77 | 72 | 64 | 85 | 83 |
| Inventory Days | 308 | 252 | 305 | 382 | 321 | 274 |
| Days Payable | 155 | 91 | 110 | 259 | 109 | 160 |
| Cash Conversion Cycle | 221 | 238 | 267 | 187 | 298 | 197 |
| Working Capital Days | 86 | 121 | 107 | 76 | -3 | -22 |
| ROCE % | 18% | 6% | 16% | 14% | 13% |
Documents
Announcements
- Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
-
Closure of Trading Window
- Trading window closed from September 1, 2026 until 48 hours after Q1 FY26 results.
-
Intimation Under Regulation 8(2) Of The SEBI (Prohibition Of Insider Trading) Regulations, 2015.
- Intimation under Regulation 8(2) enclosing fair disclosure code for UPSI.
-
Disclosure Under Regulation 30(5) Of SEBI (LODR) Regulations, 2015.
- Company authorized three KMPs to determine materiality and make stock exchange disclosures.
- Listing of Equity Shares of Symbiotec Pharmalab Ltd
Annual reports
No data available.